Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Perflenapent - NuvOX Pharma

Next Previous
Drug Profile

Perflenapent - NuvOX Pharma

Alternative Names: DDFPe; Dodecafluoropentane; NanO2; NVX 208; NVX-108; Perfluorocarbon; Perfluoropentane; PFP

Latest Information Update: 28 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NuvOx Pharma
  • Class Anti-ischaemics; Antianaemics; Antihaemorrhagics; Antineoplastics; Fluorocarbons; Neuroprotectants; Radiation-sensitising agents; Radiosensitisers; Small molecules; Vascular disorder therapies
  • Mechanism of Action Oxygen carriers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sickle cell anaemia; Glioblastoma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Adult respiratory distress syndrome; Glioblastoma; Stroke
  • Phase I Respiratory distress syndrome
  • Preclinical Haemorrhagic shock; Myocardial infarction; Traumatic brain injuries
  • No development reported SARS-CoV-2 acute respiratory disease; Sickle cell anaemia; Triple negative breast cancer

Most Recent Events

  • 28 Oct 2025 No recent reports of development identified for preclinical development in SARS-COV-2 acute respiratory disease in USA (IV, Infusion)
  • 28 Oct 2025 No recent reports of development identified for preclinical development in Sickle-cell-anaemia in USA (IV, Infusion)
  • 28 Oct 2025 No recent reports of development identified for preclinical development in Triple-negative-breast-cancer in USA (IV, Infusion)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top